We do the research together

Open positions available! Contact us for more information.

Prof. Dr. med. Jan-Henning Klusmann

Jan-Henning is an ERC grant-holder, Professor, and Director of Pediatrics & Pediatric Oncology at the University Hospital of Halle.

Prof. Dr. rer. nat. Dirk Heckl

Dirk is a Max Eder Fellow and Professor at the University Hospital of Halle. He specializes in CRISPR-Cas9 systems and modeling leukemia in mice.

PD. Dr. med. Jessica Höll

Jessica is a physician and junior group leader at the University Hospital of Halle. Her research centers on the role of RNA-binding proteins in leukemia.

Dr. Raj Bhayadia

Raj (postdoctoral fellow) works on patient-dervied xenograft models of pediatric AML, in vivo non-coding RNA studies, and pre-clinical drug testing.

Dr. Daniela Bräuer-Hartmann

Daniela (postdoctoral fellow) works on mapping the interactomes of the GATA1 / GATA1s transcription factors.

Dr. Hasan Issa

Hasan (postdoctoral fellow) works on delivering lipid nanoparticle-based oligonucleotides into AML cells, towards RNA-centered therapies.

Oriol Alejo

Oriol (PhD student, independent) is investigating the interactive genetic network of the stem cell microRNA cluster miR-99a/105~125b.

Michelle Ng

Michelle (PhD student, HBRS Molecular Medicine) is using a CRISPR interference-based screening platform to investigate long non-coding RNAs in AML.

Lonneke Verboon

Lonneke (PhD student, independent) is investigating interactions within the DLK1-DIO3 non-coding RNA locus in normal and malignant megakaryopoiesis.

Sofia Gialesaki

Sofia (PhD student, HBRS Molecular Medicine) is studying the interplay between chromosome 21 genes and GATA1s in Down syndrome AML.

Dorit Schneider

Dorit (PhD student, HBRS Molecular Medicine) is studying the deregulated network in Ezh2-mutated AML using state-of-the-art CRISPR-Cas9 technology.

Lucie Gack

Lucie (technician) supports the in vitro aspect of all non-coding RNA projects.

Alumni

Maurice Labuhn

Maurice (PhD student, HBRS Molecular Medicine) is using a lentiviral CRISPR-Cas9 system to model Down syndrome AML in vivo and in vitro.

David Mir-Salim

David (medical student, UKH) is performing drug testing on patient-dervied xenografts in vivo to find new potential therapies for childhood AML.